Interested in working with us? Call us on 703.591.0067 or fill out this quick form and we will contact you within 24 hours!

FDA Identifies Potential Problem Drugs...
Posted on 9/10/2008
New Clinical Study Casts Doubt About The Safety of Diabetes Drugs...
Posted on 9/13/2007
Last year, Congress ordered the Food & Drug Administration (FDA) to post quarterly listings of medications under investigation. The FDA released its first quarterly listing this month, identifying the following drugs as under investigation:
1. R-Gene 10, a growth hormone, pediatric overdose due to labeling/packaging confusion.
2. Suprane, an anesthetic, cardiac arrest.
3. Cymbalta, for depression and other conditions, urinary retention.
4. Intelence, an HIV medication, bleeding into joints.
5. Carac and Kuric, creams for skin conditions and fungal infections, name confusion.
6. Heparin, a blood-thinner, serious allergic reactions.
7. Extraneal, used in kidney dialysis, low blood sugars.
8. Humilin R, for diabetes, dosing confusion.
9. Stromectol and Warfarin, an anti-parasite drug and a blood thinner, drug interaction.
10. Tykerb, for advanced breast cancer, liver damage.
11. Revlimid, for multiple myeloma, severe skin blistering and bleeding.
12. Tysabri, for multiple sclerosis, skin melanomas.
13. Nitrostat, for angina, overdose due to labeling confusion.
14. Sandostatin LAR, for abnormal bone growth, bowel obstruction.
15. Oxycontin, a pain killer, drug misuse, abuse and overdose.
16. Definity, used in cardiac imaging, cardiopulmonary reactions.
17. Dilantin injection, for epileptic seizures, serious skin reaction.
18. Seroquel, for bipolar disorder, overdose due to sample pack labeling confusion.
19. Tyzeka, for chronic hepatitis B, nerve damage.
20. Tumor Necrosis Factor (TNF) Blockers, for juvenile arthritis, cancers in children and young adults.
Read More About FDA Identifies Potential Problem Drugs...
Shevlin Smith
3975 University Drive
Suite 405
Fairfax, VA 22030
Phone: (703) 591-0067
Fax: (703) 591-1877
Get Directions